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ABSTRACT

A MARKOV MODEL OF SECONDARY PREVENTION OF OSTEOPOROTIC
HIP FRACTURES
Stephanie Tapp
December 18, 2003

Low-trauma fractures of older women are a major public health burden.
Fractures of the hip and spine are some of the primary causes of chronic pain,
functional impairment, and disability among the elderly [1].
The underlying cause of these fractures is osteoporosis. Although the disease
is common, only a small proportion (15%-20%) of women at risk currently receive
preventative treatment [2].
We have focussed our attention to white postmenopausal women who have
sustained a fracture of the distal radius. We developed a Markov model using
probabilities obtained from recent literature in order to evaluated the effects of
three hypothetical interventions targeted towards women after presenting with a
wrist fracture. We analyzed this model using Monte Carlo simulations.
Our results indicate that if an intervention can be developed for this
population, then mean survival can be increased and the number of subsequent hip
fractures can be decreased.
iv
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CHAPTER I
INTRODUCTION
During the first 25 to 30 years of a woman’s life, new bone is made faster
than existing bone is broken down. During the next 10 to 20 years, bone is broken
down at about the same rate as bone is made. During menopause, inadequate
estrogen causes accelerated bone loss. In women between the ages of 45 and 55
(soon after menopause), bone begins to break down faster than new bone is made.
Bone loss in women varies but usually occurs at a faster rate (up to 6% per year)
during the first few years after menopause, then tapers to 2% per year thereafter.
Without effective prevention, a woman can lose 20%-30% of her bone mass during
the first 10 years of menopause.

A

Osteoporosis

1

Definition
In 1990, the consensus development panel defined osteoporosis as a “disease

characterized by low bone mass and microarchitectural deterioration of bone tissue,
leading to enhanced bone fragility and a consequent increase in fracture risk [2].”
The World Health Organization categorizes osteoporosis based on patients’
increased susceptibility to fractures of the hip, spine, and wrist [4].
Although accurate, these definitions are difficult to apply in clinical practice.

Figure 1. Here, a portion of a bone showing signs of osteoporosis (right) is contrasted
with a portion of a healthy bone (left). Bones weakened by osteoporosis are much
more vulnerable to fracture than are denser healthy bones [3].

Instead, physicians usually use the occurrence of a non-traumatic fracture to
consider a diagnosis of osteoporosis. Unfortunately, the presence of fractures usually
implies advanced disease [4].
The risk of fracture is inversely proportional to bone mineral density. Since
fracture risk is a continuum, it is misleading to say that osteoporosis is “present” or
“absent” [2]. However, for practical purposes, researchers have defined a cutoff value
for osteoporosis as a bone mineral density that is 2.5 standard deviations less than
the average value for young adults. This is illustrated in Table 1. According to this
cutoff value, approximately 30% of postmenopausal women at the highest risk of

2

TABLE 1
Diagnostic categories for osteoporosis in postmenopausal women according to DXA
measurements based on World Health Organization Criteria [5, 6].

Category
Normal
Osteopenia
Osteoporosis
Severe Osteoporosis

Definition by bone density
A value for BMD that is not more than 1 SD below the young
adult mean value.
A value for BMD that lies between 1 and 2 SD below the
young adult mean value.
A value for BMD that is more than 2.5 SD below the young
adult mean value.
A value for BMD more than 2.5 SD or below the young adult
mean in the presence of one or more fragility fractures.

fracture are identified [1].
2

Incidence and Prevalence
The prevalence of osteoporosis is difficult to gauge, since it can be defined by

the number of fractures incurred or in terms of bone mineral density in relation to
the average young adult population [7]. Regardless, osteoporosis is the most
common disorder of the bone [8], and one of the most prevalent chronic health
conditions among the elderly [2].
Prior to menopause, few women have osteoporosis, but the incidence and
prevalence of the disease increases with age due to progressive loss of bone after
menopause [2, 5]. While approximately 15% of young adults have osteopenia, only
about 0.6% have osteoporosis (as defined in Table 1). By age 60-70 years, for every
nine women: five have osteopenia, three have osteoporosis, and only one has normal
bone mineral density. By age 80 years, at least 70% of women have osteoporosis [2].

3

Based on these figures, about 54% of postmenopausal white women in the United
states have osteopenia and between 25% and 30% have osteoporosis [2, 4, 9].
Estimates predict that more than half of the women in the United States will
experience an osteoporotic fracture during their lifetime [2].
Osteoporosis is recognized as a significant public health problem because of
the increased morbidity and mortality associated with its complications. Untreated
osteoporosis can lead to bone fractures that may result in permanent disability. In
fact, fractures at most sites in the elderly can be traced to osteoporosis [10].
3

Risk Factors for Bone Loss
Risk factors for osteoporosis and osteoporotic fractures have been determined

and are used to identify the need for further evaluation. In women, the loss of
estrogen at menopause is the major change leading to bone loss [8], but other risk
factors such as advanced age, reduced physical activity, smoking and alcohol abuse
contribute additively to bone loss [11]. Risk factors can be categorized as modifiable
and non-modifiable as represented in Table 2.

B

Osteoporotic Fractures

1

Fragility Fractures
A fragility fracture is a fracture that is due to minor trauma. Most fragility

fractures in the elderly are due to the type of injury that would not cause fractures
among normal healthy adults. In fact, as many as 90% of hip and wrist fractures
among the elderly in the United States are associated with mild trauma, such as a
fall from standing height or lower [2]. Unfortunately, just as the risk of developing

4

TABLE 2
Risk factors for osteoporosis [5].

Modifiable
Inadequate exercise
Inadequate nutrition
Calcium
Vitamin D
Smoking
Alcohol Abuse
Medicaitons
Glucocorticoids
Benzodiazepines
Anticonvulsants
Thyroid Hornones

Non-modifiable
Age
Gender
Race
Early Menopause
Family history of fractures

osteoporosis increases in the elderly, so does the propensity to fall [12].
Fragility fractures are considered the “hallmark” sign of osteoporosis. Other
diseases exist such as bone tumors or bone marrow abnormalities that can lead to
bone deterioration, but osteoporosis is the most common cause of brittle bones .
Since osteoporosis is asymptomatic, most patients are not diagnosed until a
fracture occurs. The three most common osteoporotic fracture sites are the spine,
wrist, and hip. A white postmenopausal woman’s lifetime risk of having a one of
these fractures is 40-50% [2, 11, 13, 14, 15, 16]. This risk is expected to approach
75% in the future [17]. Adults who have sustained one fracture are more likely to
have another fracture of a different type [18]. By age 90, 33% of women will have
sustained a hip fracture [19]. A consequence of osteoporotic fractures is a reduction
in the quality of life. Anxiety, depression and social loss have all been linked to
osteoporosis [11].

5

Figure 2. Illustration of radial (Colles) fracture.

2

Wrist Fractures
About one-third of all women aged 65 and older fall each year, but only 1%

to 2% of these women break their wrists [20]. Even so, fracture of the distal radius
is the most common breakage in peri-menopausal women. Fifteen to sixteen percent
of white women will fracture their wrist after age 50 [18, 20, 21, 22]. Among women
in the United States, the incidence of wrist fracture increases rapidly around the
time of menopause, then plateaus after age 60 years [2].
Rozental et. al. studied the effect of distal radius fracture on mortality. They
concluded that, “Mortality rates after distal radius fractures in our patient cohort
were significantly higher than those of the standard US elderly population. The
estimated survival in our cohort was 14% less than expected for elderly US residents
from all causes of death [23].” The increase in mortality may be associated with
comorbid conditions or with the radial fracture’s limiting mobility and
independence, which possibly increased the probability of death [23].

6

Figure 3. [24]

Radial fractures are the least morbid of osteoporotic fractures. By three years
after a wrist fracture, 75% of patients regain almost full function, with 25% of
patients experiencing variable loss of wrist strength [11].
3

Vertebral Fractures
Although vertebral fractures are the most common fractures that can be

directly attributed to osteoporosis, less is known about their epidemiology because
approximately two thirds are asymptomatic and go undetected [5, 16]. It is
estimated that the lifetime risk for a clinically evident vertebral fracture is
approximately 16% in white women [4].

7

4

Hip Fractures
By far the most morbid osteoporotic fractures are those involving the hip.

Consequently, one of the primary aims of public health measures targeted towards
the elderly is hip fracture prevention. From an economic viewpoint, prevention of
these fractures is important, because most patients require inpatient surgical
treatment and many subsequently need increased costly nursing-home care [25]. In
fact, the total 1995 health expenditures for osteoporotic fractures amounted to 1.5%
of National Personal Health Care Expenditures and 2.4% of National Hospital Care
Expenditures. Most of this cost is directly attributable to hip fractures [10].
More than 90% of hip fractures are associated with osteoporosis [15]. Most
mortality associated with osteoporosis is related to hip fractures [2]. One year hip
fracture mortality rates of up to 36% [25, 26], have made hip fractures solely
responsible for launching osteoporosis into the category of life-threatening disease
[4]. As the worlds population ages, hip fractures become more frequent [8].
The incidence of hip fractures rises exponentially with increasing age after
about 50 years. The incidence rate among women in the United States ranges form
about 2 per 1000 patient-years at age 65 years to a peak of about 30 per 1000
patient-years after age 85 years [2, 5]. For white women aged 50 years or older, the
lifetime risk of hip fracture is approximately 17%, and estimates are that 33% of
women will sustain at least one hip fracture by the age of 90 [4].
The duration of excess mortality attributable to hip fracture has not yet been
definitively established. According to Richmond, et. al., the greatest mortality risk
is in the first six months of fracture with the risk approaching expected mortality
after 6 months [26]. Ross, et. al. suggests that most of the increased mortality
occurs during the initial 6 to 12 months after the fracture[2]. But, according to
8

Srivastava, et. al. it might take as long as 1 to 2 years for mortality rates return to
normal for the hip fracture population [5].
Theodorou et. al. give the mortality rate after hip fractures treated
operatively as 5% to 25% within the first 3 months [4]. Overall, the fatality rate at
one year post-fracture is between 21% and 24% [4, 10, 11, 15]. In a study by
Mellinger, et. al., life expectancy one year after surgery to repair a hip fracture was
7 years, as opposed to 16-20 years for the average person [27].
Hip fractures are arguably the most serious outcome of osteoporosis and are
associated with substantial long-term difficulties [8]. Compared with other
osteoporotic fractures, fractures of the hip incur the greatest morbidity and direct
medical costs for health services [10]. The consequences of hip fractures include
hospitalization, lengthy stays in nursing homes and rehabilitation centers, pain,
physical impairment, loss of functional abilities, and deterioration in emotional
health and social activities [2].
At 1 year after hip fracture, 40% of patients are still unable to walk
independently, 60% are unable to perform an essential activity of daily living (e.g.,
dressing, bathing) without assistance, and 80% are unable to perform an
instrumental activity of daily living (e.g., shopping, driving) [5, 11]. In fact, only
16% of patients who sustain hip fractures regain their functional mobility one year
after surgery [27].
After hip fracture, only 50% of patients return to their pre-fracture health
state [4]. Almost 25% of formerly independent people become at least partially
dependent [5], with more than half of hip fracture survivors never regaining their
pre-fracture level of walking [25].
Almost half of the patients in a study by Magaziner et. al. were discharged
9

to an institution and more than one third were re-hospitalized during the year
following their hip fracture [28]. In 1990, the proportion of US hip fracture patients
who were discharged from hospital to nursing homes varied from 14% for those aged
50 to 55 years up to 55% for those aged 90 years [5]. Admittance to an institution
can be devastating for the patient. In a time trade-off study, Salkeld et al. reported
that a great majority of elderly women would rather die than be admitted to a
nursing home following hip fracture [29].

C

Identification of Those At Risk
Robinson, et. al. suggest that if strategies aimed at preventing hip fracture

are to be productive, then they should be targeted at subgroups that are at an
increased risk of fracture rather than the entire osteoporosis population [25]. To
identify patients at high risk of hip fracture, it is necessary to know which risk
factors are important and the magnitude of the fracture risk [30].
Currently, low bone mineral density (BMD) and past or current history of
fracture are considered the strongest predictors of future osteoporotic fractures
among elderly women [2, 11].
1

Low Bone Mineral Density
Low bone mineral density is the major risk factor for osteoporosis and the

strongest predictor of fracture risk. For every standard deviation below the young
adult mean that a BMD score falls, the risk for a fracture increases 2 to 3 times [4].
Therefore, it has been suggested that measurements of bone mass should be a
precursor to initiating medical treatment of osteoporosis [9], and some experts
suggest that all women over the age of 65 years should have a bone density test [31].
10

Several different techniques can be used to measure BMD.
Dual energy X-ray absorptiometry (DEXA):
DEXA uses two different X-ray beams. The amounts of each X-ray beam that
is blocked by bone and soft tissue are compared to estimate the bone density.
DEXA is the most accurate method for measuring BMD. It is fast and uses
very low doses of radiation. DEXA measures BMD on bones of the spine and
hip. Under good conditions, DEXA can measure as little as 2% of bone loss
per year.
Peripheral dual energy X-ray absorptiometry (P-DEXA):
P-DEXA is a modification of the DEXA technique. It measures bone density
in outlying (peripheral) areas of the body, such as the wrist. P-DEXA
machines are portable units that can be used in a doctor’s office. P-DEXA
also uses very low doses of radiation, but the results are usually obtained
faster than conventional DEXA measurements. The disadvantages of P-DEXA
include an inability to measure density of the bones (in the hip and spine)
most likely to fracture because of osteoporosis and its limited usefulness
(compared to DEXA) for monitoring the effect of medication used to treat
osteoporosis.
Dual photon absorptiometry (DPA):
DPA uses a radioactive substance (gadolinium) to produce radiation. It can
measure the density of bones in thicker parts of the body (such as the hip and
spine). DPA has a slower scan time than the other methods; however, like
other BMD techniques, DPA uses very low doses of radiation.
Ultrasound:
11

Ultrasound is generally used as an initial screening test. If results from an
ultrasound test indicate that bone density is low, DEXA is recommended to
confirm the results. Ultrasound uses sound waves to determine BMD, usually
in the heel. Some machines pass the sound waves through air and some pass
them through water. Ultrasound is rapid, painless, and does not use
potentially harmful radiation (like X-rays). One disadvantage of ultrasound is
its inability to measure density of the bones most likely to fracture (the hip
and spine) because of osteoporosis. Also, ultrasound has limited usefulness
(compared to DEXA) for monitoring and comparing the effect of medications
used to treat osteoporosis.
Quantitative computed tomography (QCT):
Quantitative computed tomography (QCT) is a type of CT scan that
measures the density of a bone in the spine). A form of QCT called peripheral
QCT (pQCT) measures the density of bones in peripheral areas of the body,
such as the wrist. Because it is expensive and results in a radiation exposure
that is 20 to 200 times greater than the other techniques, and because it is less
accurate than DEXA, P-DEXA, or DPA, quantitative computed tomography
is not usually recommended.
The most established and accessible techniques for assessing low BMD are
dual energy X-ray absorptiometry and quantitative computed tomography [9], with
dual energy X-ray absorptiometry of the hip considered the “gold standard” for
bone mineral density measurement [32]. DEXA is approved by the Food and Drug
Administration, and is precise, noninvasive, and takes only 10 minutes to administer
[5]. Unfortunately, central DEXA equipment is large, expensive, and not widely
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available. Insurance companies do not consistently cover DEXA testing costs,
especially in women younger than 65 years [9, 32].
2

Previous Fracture
Patients who sustain a fracture of the distal forearm show some similarity

regarding risk factors to those who have hip fractures [33]. The incidence of radial
fractures rises sharply at around age 55, while the incidence for hip fractures does so
at age 70 [34]. Furthermore, the incidence of wrist fracture plateaus in older women,
but the incidence of hip fractures increases exponentially to the end of life [17]. This
15 year latent period provides the opportunity to identify individuals at risk well
before fracture occurs and to initiate interventions to prevent further bone loss and
fracture [17, 33].
Several studies have demonstrated an association between a history of
low-impact fractures and a subsequent fracture [12, 25, 33, 35]. Gunnes, et al, found
that a previous fracture can predict the risk of a subsequent fracture of the hip and
spine, and this risk is independent of age [36]. Patients with a prior fracture are two
to five times more likely to have future fractures than are persons without fractures
[11, 37].
Mallmin, et. al. suggest that all patients with a fracture of the distal forearm
should be considered as potential candidates for prophylactic measures in order to
prevent further bone loss and fractures [33], but active intervention to treat
osteoporosis after a first fracture in an effort to prevent subsequent fractures is not
routine current practice. In a recent retrospective study of over 1000
postmenopausal women who had sustained a wrist fracture, only 24% underwent
either diagnostic evaluation by the clinician or treatment for osteoporosis [6]. In a
13

study by Cuddihy, et. al., it was found that the occurrence of a distal forearm
fracture did not appear to be routinely recognized by physicians or patients as a
manifestation of osteoporosis, and therefore was not a trigger for an osteoporosis
workup [38]. Similarly, Siris, et. al. found that only about 1 in 5 patients who had
been seen with a minimal trauma fracture of the hip, wrist, or spine had received
treatment for osteoporosis within the next year [32].

D

Treatment/Fracture Prevention
Certain medicines that may slow or stop bone loss, increase bone density, and

help prevent bone fractures are currently approved by the FDA for treatment of
osteoporosis, but treatment cannot eliminate the disease.
The increasing number of therapeutic options for fracture prevention require
targeting towards high-risk groups if they are to be cost-effective [30]. Where
health-service resources are limited, applying secondary prevention to high-risk
groups may be more feasible economically than treating a less narrowly defined
population [25].
Preventive strategies aim to reduce the risk of fracture either by focusing on
factors that contribute to deterioration of BMD or by introducing measures that
increase peak bone mass. However, the lag time between introducing these
strategies and seeing the effects is approximately 30 years [7].
A review of the treatment of osteoporosis indicates that prevention is the
best solution. Maximization of peak bone mass and reduction of postmenopausal
and age-associated bone loss are both crucial. The primary goal in the treatment of
osteoporosis is to prevent bone loss beyond the fracture threshold [39].
The National Osteoporosis Foundation recommends treatment to reduce
14

fracture risk for all postmenopausal women who present with vertebral or hip
fracture, women who have BMD T-scores below -2 and women who have T-scores
below 1.5 as well as additional risk factors, especially prior fracture [11].
1

Drug Therapy
Patients with the lowest BMD values and a history of prior fractures (i.e.

those at the highest risk for re-fracture), are most responsive to current US Food
and Drug Administration approved therapies [35]. Several therapeutic agents that
decrease fracture risk and increase BMD are available. The U.S. FDA has approved
five anti-reabsorption agents: estrogen, calcitonin, and alendronate, risedronate and
raloxifene. These drugs act to increase bone mineral density by slowing bone
resorption and allowing more balanced bone turnover [17].
There is a strong expression of concern regarding the cost of medication to
treat osteoporosis, but studies have shown that drugs can reduce both vertebral and
hip fractures by 30% to 60% [35, 37].
2

Hip Protectors
Researchers have been investigating the use of specially designed hip

protectors for use with patients that fall into the highest risk for hip fracture.
Kannus et. al. found that by wearing a protector at the time of the fall, the risk of
fracture can be decreased by more than 80% [40]. One weakness of this strategy is
that patients must be willing to wear the protectors. In the Kannus study, 31% of
the eligible subjects refused to wear the protectors [40].

15

E

The Current Research
The current research looks at patients who have sustained a prior fracture of

the distal radius as a target group for osteoporosis treatment and hip fracture
prevention. A Markov model has been developed using probabilities obtained from
recent literature.
We analyzed our Markov model using Monte Carlo simulations. We have
computed the increase in survival and number of fractures avoided based on
hypothetical interventions. We began by assuming that a wrist fracture imparts a
2-fold increase in the probability of sustaining a subsequent hip fracture. We
changed our model in order to calculate the effect of 3 hypothetical interventions
that could be used for every patient that presents with a wrist fracture. These
interventions are categorized by the amount they reduce the excess fracture risk.
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CHAPTER II
MODEL OF THE PROBLEM
As was discussed in the previous chapter, a fracture of the distal radius is a
risk factor for a subsequent hip fracture. This led us to ask the following: “If every
woman who presents with a distal radius fracture is treated for osteoporosis, how
many hip fractures can we hope to prevent, and how much potential life can be
gained?”
We chose to model postmenopausal white women because they represent the
group at highest risk for osteoporosis, and because the majority of the literature has
focussed on this group.

A

Markov Model
For any given woman, it is uncertain whether she will experience a wrist

fracture or hip fracture during her lifetime. In addition, if such a fracture is to
occur, it is impossible to predict when or how often. Since the risk is ongoing over
time, we decided to analyze the problem using a Markov model. The events of
importance are incidences of hip and wrist fractures as well as death from all causes
and, specifically, death from hip fractures.
A Markov model assumes that the patient is always in one of a finite number
of health states referred to as Markov states. In our model, the Markov states are
Well, Hip Fracture, Death From All causes, and Death From Hip Fracture. Each

Dead
From All
Causes

Well

Hip
Fracture

Dead
From Hip
Fracture

Figure 4. Markov-state diagram. Each circle represents a Markov state. Arrows
indicate allowed transitions.

event is modelled as a transition from one state to another.
The time horizon of the analysis was approximately 60 years. This was
broken down into equal increments of time called Markov cycles. We chose a cycle
length of six months because the literature suggests that the major events that
trigger mortality after a hip fracture occur at 6 month intervals post-fracture.
During a cycle, a patient may make a transition from one state to another.
In order to develop and analyze our model, we used the software package
DATA 4.0 (TreeAge software, Williamstown, PA).
Figure 4 shows an illustration of the Markov process as a state-transition
diagram. Each circle represents a Markov state. Allowed transitions are indicated
by arrows connecting two different states. Arrows leading from a state to itself
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indicate that the patient may remain in that state in consecutive cycles. Only
certain transitions are allowed. Patients in either of the Dead states cannot make a
transition to any other state (for obvious reasons). It is assumed that a patient in a
given state can make only a single state transition during a cycle.
The Markov-state diagram in Figure 4 lays out all of the possible paths that
an individual patient may take (e.g. Well to Hip Fracture to Well to Dead, or Well
to Hip Fracture to Well to Well ). However, there is no way of knowing which paths
are more or less likely. So, we calculate the net probability of making a transition
from one state to another during a single cycle and assign this transition probability
to each allowed transition. Once this was done, the entire Markov process is defined.
In order for a Markov process to terminate, it must have at least one state
that a patient cannot leave called an absorbing state. In our model, like most
medical examples, the absorbing states are the Death states. We have chosen to
include two separate Death states in order to keep track of the cause of death.

B

The Markov-Cycle Tree
Although a transition-state diagram like Figure 4 is useful when organizing a

Markov process, it may be difficult to analyze. Instead, we convert the diagram to a
Markov-cycle tree as shown in Figure 5.
Refer to Figure 4. From the Well state, it is possible to have a transition to
the Hip Fracture state, the Dead from all causes state or back to the Well state.
From the Hip Fracture state, transitions to either the Well state or the Dead from
Hip Fracture state are possible. In our Markov-cycle tree, the transitions from a
state are represented by the subtree emanating from that state. Notice that we can
trace every transition shown in Figure 4 if we follow paths from the initial branches
19

to the terminal nodes in Figure 5.
Initial state probabilities are entered below the initial Markov state branches.
These are the probabilities of beginning the process in a particular state and must
sum to 1.0. In our model, everyone begins in the Well state. Initial probabilities are
used only once during the evaluation of a Markov model, to specify the initial
distribution of the cohort at the beginning of stage 0. All subsequent movement
through the model utilizes transition probabilities, which will be specified under the
branches to the right of the initial Markov states.
Tracker variables can be used to give a model memory during Monte Carlo
simulation trials. In our model, we’ve used tracker variables to keep track of the
number of hip and wrist fractures, to count the number of deaths from hip fracture,
to keep track of the age at which hip fractures occur, and to force a choice at logic
nodes. A list of the tracker variables used in the model along with their definition
can be found in Table 3.
Our model employs two logic nodes. A logic node selects one path from its
branches; rather than looking at expected values, it chooses a path by evaluating
logical expressions. Each of its branches has an expression associated with it;
starting at the top branch, the first node with an expression that evaluates to true
is selected.
Markov state reward information is shown in Figure 8. Each states initial
reward expression is evaluated only during stage 0. It will be accumulated only by
the portion of the cohort that is initially distributed to that state. The incremental
reward is accrued by the membership of the state at each subsequent stage of the
process, starting at stage 1 and continuing until the process terminates. In the final
stage of the process, when the termination condition evaluates to true, the
20
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age=45+(0.5)*(_stage)

Osteoporosis Markov
6 month increments

1

#

#

tMortPostHip[age-track_age_hip]

Die

Survive

Stay Alive

tRegMort[age]

#

Dead from Hip Fracture

#

stay in post-fracture state

(age-track_age_hip)>1

return to healthy

tProbWristFracture[age]

{T} Track_wrist_fracture=Track_wrist_fracture+1

Wrist Fracture

Stay Well

Dead from all causes

still excess mortality
risk associated
with hip fracture

no longer excess
mortality associated
with hip fracture

Well

#

prior wrist
fracture

Track_wrist_fracture=0

NO prior
wrist fracture

1

n * tProbHipWithWrist[age]

Hip Fracture

Well

{T} AgeH1=if(Track_hip_fracture=1;age;AgeH1)
{T} AgeH2=if(Track_hip_fracture=2;age;AgeH2)

#
{T} track_age_hip=age
{T} Track_hip_fracture=Track_hip_fracture+1

Hip Fracture

Well

1

Stay Well

tProbHipFracture[age]

Well

{T} AgeH1=if(Track_hip_fracture=1;age;AgeH1)
{T} AgeH2=if(Track_hip_fracture=2;age;AgeH2)

#
{T} track_age_hip=age
{T} Track_hip_fracture=Track_hip_fracture+1

Hip Fracture

Stay Well

Figure 5. Tree Representation of the Model. Close up views can be found in Figures 6 and 7.

0

Dead from Hip Fracture

0

Dead from all causes

0

Hip Fracture

Well

Die

Hip Fracture

Hip Fracture
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age=45+(0.5)*(_stage)

Osteoporosis Markov
6 month increments

1

#

#

tMortPostHip[age-track_age_hip]

Die

Survive

Logic
Node

Stay Alive

tRegMort[age]

#

Dead from Hip Fracture

#

stay in post-fracture state

(age-track_age_hip)>1

return to healthy

tProbWristFracture[age]

still excess mortality
risk associated
with hip fracture

no longer excess
mortality associated
with hip fracture

Well

#

prior wrist
fracture

Track_wrist_fracture=0

NO prior
wrist fracture

This difference is the time that
has elapsed post-fracture. If this
is 6 months or 1 year, then the
patient is sent back to the "Hip
Fracture" node where the table
tMortPostHip includes greater
mortality risk.

{T} Track_wrist_fracture=Track_wrist_fracture+1

Wrist Fracture

Stay Well

Dead from all causes

Figure 6. Close-up annotated view of the tree in Figure 5.

0

Dead from Hip Fracture

0

Dead from all causes

0

Hip Fracture

Well

Die

Hi

W
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The value of "n" can be changed
to represent the effectivness of
hypothetical interventions.

Tracker variables record
the patient's age at the
first and second hip
fracture.

Hip Fracture

Hip Fracture

Figure 7. Close-up annotated view of the tree in Figure 5. (Continuation of Figure 6)

ip Fracture

Tracker variables record
total number of hip
fractures as well as the age
of the patient at the time of
the most recent hip fracture.

1

n * tProbHipWithWrist[age]

Well

{T} AgeH1=if(Track_hip_fracture=1;age;AgeH1)
{T} AgeH2=if(Track_hip_fracture=2;age;AgeH2)

Well

{T} track_age_hip=age
{T} Track_hip_fracture=Track_hip_fracture+1

Hip Fracture

#

1

Stay Well

tProbHipFracture[age]

Well

{T} AgeH1=if(Track_hip_fracture=1;age;AgeH1)
{T} AgeH2=if(Track_hip_fracture=2;age;AgeH2)

#

{T} track_age_hip=age
{T} Track_hip_fracture=Track_hip_fracture+1

Hip Fracture

Stay Well

incremental state reward will not be accumulated, but the final reward will.
Since the entire cohort is initially distributed in the Well state, this is the
only state with an initial reward. The incremental reward of 0.5 for the Well state
and the Hip Fracture state gives a patient credit for each cycle spent in these two
non-Dead states. The incremental reward is 0.5 since we have chosen a cycle length
of 6 months. In effect, the incremental reward keeps track of how long the patient
lives.
The initial reward for the Well state is 0.25 instead of 0.5. DATA suggests
this half-cycle correction in order to improve Markov process approximations.
Real processes occur in continuous time, with transitions and other
events occurring throughout an interval of time. In DATA, however, a
Markov process occurs as a discrete sequence of snapshots, with
transitions always occurring at the end of a stage. Without some kind
of correction, the approximations inherent in discrete simulation of a
real process can lead to significant errors in the calculation of average
values in a cohort analysis, and individual values in Monte Carlo trials.
[User’s Manual, DATA 4.0]

24

Well
--- Markov Information
Init Rwd: .25
Incr Rwd: .5
Final Rwd: 0

[+]

1

Hip Fracture
--- Markov Information
Init Rwd: 0
Incr Rwd: .5
Final Rwd: 0

Osteoporosis Markov
6 month increments
age=45+(0.5)*(_stage)
--- Markov Information
Term: _stage > 10 & (_stage > 120 | _stage_reward < .01)

[+]

0

Dead from all causes
--- Markov Information
Init Rwd: 0
Incr Rwd: 0
Final Rwd: 0

0

Markov Termination:

Dead from Hip Fracture
--- Markov Information
Init Rwd: 0
Incr Rwd: 0
Final Rwd: 0

The process will continue
for a maximum of 120
cycles. (60 years)

0

Figure 8. Markov state information. Note that a half-cycle correction has been used
in the initial reward for the Well state.
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1

Transition Probabilities
At the beginning of our tree, we define a variable age. Since most fractures

occur after age 45, we’ll use this as our start age. As a patient completes a cycle in
the model, they grow older. DATA automatically keeps track of the number of
cycles that have been traversed in a variable called _stage. In our model, cycle
length is 6 months, so we can imagine patients aging 6 months by the end of a cycle.
So, at the beginning of every cycle, we’ll compute age using the following formula:

age = 45 + (0.5)(_stage)

(1)

For our transition probabilities, we created tables indexed by age. A list of all
variables used in the model can be found in Section 2.
The probabilities given in the literature for rates of hip fracture, wrist
fracture and mortality are given in years. Our Markov-cycle duration is 6 months.
We cannot simply divide the transition probabilities by 2 to arrive at the
approximate transition probabilities for the shorter cycle. Instead we compute the
bi-annual probabilities using the formula
p = 1 − e−r/2
where r is the annual rate.
2

Model Variables
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(2)

TABLE 3
Tracker variables used in the tree in Figure 5.

Variable

Definition

{T} AgeH1

if(Track_hip_fracture=1;age;AgeH1)

{T} AgeH2

if(Track_hip_fracture=2;age;AgeH2)

{T} track_age_hip

age

{T} Track_hip_fracture

Track_hip_fracture+1

{T} Track_wrist_fracture

Track_wrist_fracture+1

{T} dead_from_hip

dead_from_hip+1

TABLE 4
Data compiled from tables found at the CDC web-site [41].

National All Causes Mortality
White, Non-Hispanic, Women by Age, 1997-2000
AGE:
MORTALITY:

45-54
280.7

55-64
739

65-74
1911

75-84
4788.5

Mortality (Rate p. 100,000)
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85+
14798.2

TABLE 5
tRegMort used in the model. (Bi-annual all-cause mortality rate). Converted from
figures in Table 4 using Equation 2.

Age

Mortality Rate

45-54

0.002807

55-64

0.007390

65-74

0.019110

75-84

0.047885

85+

0.147982
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TABLE 6
tProbHipFracture used in the model. Hip fracture probabilities compiled from Lauritzen [12] and Kannus [40]. Converted to bi-annual probability using equation 2.

age
45-49
50-54
55-59
60-64
65-69
70-74
75-79
80-84
85-89
90-94
95+

Probability of
Hip Fracture
0.000454897
0.0020479
0.004539664
0.009009172
0.01916399
0.040026885
0.080982395
0.154815219
0.228292742
0.03165805
0.037835649
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TABLE 7
tProbWristFracture used in the model. Wrist fracture probabilities compiled from
Lauritzen [12] and Kannus [40] were converted to bi-annual probability using equation
2.

Probability of
Wrist Fracture
0.001114379
0.001498876
0.002496878
0.004987521
0.007968085
0.0124222
0.018820638
0.018820638
0.018820638
0.020291304
0.005494848

age
45-49
50-54
55-59
60-64
65-69
70-74
75-79
80-84
85-89
90-94
95+

TABLE 8
tMortPostHip used in the model. Mortality following hip fracture.

Probabilty of Death
0-6 Months

0.35

6-12 Months

0.25
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CHAPTER III
MONTE CARLO SIMULATION
A

Analysis
For our analysis, we modelled four separate hypothetical intervention

strategies based on their level of effectiveness. The DATA 4.0 software offers two
ways to evaluate a Markov model: Markov cohort simulation and Monte Carlo
simulation. We chose to analyze our model using Monte Carlo simulation trials. In
a single first-order trial of our Markov model, one member of a hypothetical cohort
is randomly stepped through the process, based on the probabilities in the model.
Our tracker variables helped us track each individual’s particular steps through the
process. This created a form of memory that we used in determining transitions. At
the end of each cycle, a random-number generator was used together with the
transition probabilities to determine in which state the patient would begin the next
cycle. The patient is given credit for each cycle spent in a non-Dead state. Each
trial generates a survival time. After a large number of trials, these constitute a
distribution of the survival values. We can calculate the mean and standard
deviation for this distribution.
We performed four separate Monte Carlo simulations consisting of 10,000
trials on our model in Figure 5. For each simulation, we changed the value of n (See
Figure 9) based on the effectiveness of our hypothetical intervention. The values

tRegMort[age]

Stay Alive

NO prior
wrist fracture

Stay Well

Track_wrist_fracture=0

Hip Fracture

Stay Well
#

#
tProbHipFracture[age]
Stay Well

prior wrist
fracture

#
#

Well

1
Well

Hip Fracture
n * tProbHipWithWrist[age]

Hip Fracture

1

Hip Fracture

The value of "n" can be
changed to represent the
effectivness of
hypothetical interventions.

Figure 9. Four Monte Carlo simulations were run, each using one of the values for n
found in Table 9

used are summarized in Table 9.
A wrist fracture imparts an approximate 2-fold increase in the risk of a
subsequent hip fracture [12, 11]. Our hypothetical interventions model the effect of
reducing this increase by increments of 0.5.
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TABLE 9
These values were substituted into the model and four separate Monte Carlo simulations were performed. (Refer to Figures 5 and 9).

Value of n

B

No Intervention

2.0

Moderate Intervention

1.5

Effective Intervention

1.0

Highly Effective Intervention

0.5

Results
The mean survival for each of the four intervention groups is given in

Table 10. An intervention that decreases the risk of a hip fracture after a wrist
fracture from 2 to 1.5, 1.0, or 0.5 can increase life expectancy by 0.271, 0.557, or
1.049 years, respectively.
The number of patients that experienced zero fractures was 190 greater in the
Effective Intervention group and 490 greater in the Highly Effective Intervention
group (Table 11). Of patients who did experience fractures, there were between 140
and 240 fewer patients who experienced a second fracture in the intervention groups
compared to the no-intervention group (Table 12).
Tables 13 and 14 illustrate that interventions can delay the occurrence of a
first or second hip fracture following a wrist fracture.
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TABLE 10
Comparison of expected survival (in years) for the four groups.

No
Intervention

Moderate
Intervention

Effective
Intervention

Highly Effective
Intervention

Mean

27.846

28.117

28.403

28.895

Std Dev

9.217

9.278

9.682

9.921

0.271

0.557

1.049

Effect of Intervention

TABLE 11
Results of Monte Carlo Simulations. Number of patients (out of 10,000) who experienced zero hip fractures.

Number of
Patients

Difference Due
to Intervention

No Intervention

2590

Moderate Intervention

2600

10

Effective Intervention

2780

190

Highly Effective Intervention

3080

490
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TABLE 12
Results of Monte Carlo simulations. Number of patients (out of 10,000) who experienced a second hip fracture.

Number of
Patients

Difference Due
to Intervention

No Intervention

1590

Moderate Intervention

1450

-140

Effective Intervention

1410

-180

Highly Effective Intervention

1350

-240

TABLE 13
Results of Monte Carlo simulations. Distribution of age at time of first hip fracture.

No
Intervention

Moderate
Intervention

Effective
Intervention

Highly Effective
Intervention

45-49

0.005

0.005

0.005

0.004

50-54

0.021

0.021

0.022

0.021

55-59

0.042

0.043

0.041

0.04

60-64

0.08

0.072

0.068

0.072

65-69

0.144

0.136

0.125

0.119

70-74

0.194

0.193

0.181

0.166

75-79

0.178

0.185

0.179

0.159

80-84

0.067

0.076

0.089

0.087

85-89

0.009

0.01

0.012

0.021

90-94

0

0

0

0.001

95-99

0

0

0

0.001
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TABLE 14
Results of Monte Carlo simulations. Distribution of age at time of second hip fracture.

No
Intervention

Moderate
Intervention

Effective
Intervention

Highly Effective
Intervention

45-49

0

0

0

0

50-54

0

0

0

0

55-59

0.001

0.001

0.001

0

60-64

0.004

0.002

0.003

0.002

65-69

0.011

0.009

0.008

0.008

70-74

0.038

0.034

0.028

0.025

75-79

0.081

0.072

0.062

0.056

80-84

0.074

0.072

0.075

0.06

85-89

0.019

0.021

0.026

0.027

90-94

0

0

0.001

0.001

95-99

0

0

0

0.001
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C

Discussion
The results of this analysis show that if all patients that present with a wrist

fracture are treated with an successful intervention, then it is possible to increase
survival in post-menopausal white women. Even for a moderate intervention, we
can gain up to 3 months average survival. This is encouraging, given the number of
women at risk of sustaining a hip fracture following a fracture of the distal radius.
A gain of up to one year of life for highly effective interventions shows that an
exploration of aggressive therapies is worthwhile.
Our analysis has shown that if an Effective treatment is targeted toward a
sample of 10,000 women, then we can prevent up to 190 post-wrist hip fractures.
For a Highly Effective treatment, this number rises to 490.
The number of avoided hip fractures is important in light of a recent study by
Braithwaite, et. al. in 2003, where the lifetime attributable cost of hip fracture was
calculated to be $81,300 [42]. Table 15 contains a simple cost analysis. From these
figures, it seems reasonable to assume that cost-effective interventions are possible.

D

Suggestions For Further Research
Our primary aim in this research was to find the amount of life that could be

gained and the number of fractures that could be avoided. It is our opinion that
these numbers suggest that future research is warranted.
We have developed a model that estimates years of survival. Although this is
important, it does not capture the complexity of the entire hip fracture problem.
Hip fractures incur tremendous morbidity. So, by preventing a hip fracture, we not
only prolong a patient’s life, but also sustain that patient’s quality of life.
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$15,447,000.00

$39,837,000.00

490

Highly Effective Intervention

$813,000.00

190

10

Estimated
total cost of
fractures

Effective Intervention

Moderate Intervention

number of first
fractures avoided
(per 10,000)

$3,983.70

$1,544.70

$81.30

Break-Even
Treatment Cost
(per woman)

Osteoporosis Medication.

Hormone replacement therapy

Interventions listed above, plus:

eyeglasses, calcium supplements.

decrease balance, evaluation of need for

Review of prescriptions that might

Interventions listed above, plus:

exercise.

nutrition, and weight bearing

Patients given advice on home safety,

Types of feasible
intervention

TABLE 15. Crude estimates of cost-effectiveness based on figures from Braithwaite, et. al. [42] (Cost of hip fracture
estimated at $81,300).

A future study that examines the quality of life related to osteoporotic
fracture could compute Quality Adjusted Life Years (QALY’s) that are comparable
among various diseases.
Formal decision analysis could be used to determine the most useful
interventions. Cost-effectiveness analysis could determine if we could develop
interventions that are worthwhile.
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CHAPTER IV
CONCLUSION
Physicians often regard fractures of the spine, wrist, and hip as quintessential
osteoporotic fractures [39]. However, it is often the case that even when women
present with these fractures, they remain undiagnosed for osteoporosis and therefore
many are not treated. Since a significant proportion of osteoporotic fractures occur
in peri-menopausal women with substantial life expectancy, secondary prevention is
important [43].
Osteoporotic fractures are associated with higher health care costs, physical
disability, impaired quality of life, and increased mortality. Because the incidence of
osteoporotic fracture increases with advancing age, measures to diagnose and
prevent osteoporosis and its complications assume a major public health concern [5].
The vast majority of men and women at risk for osteoporosis never visit
specialists, and the relatively small numbers who do, do so when the disease process
is advanced-generally after at least one fracture has occurred or bone is seriously
compromised, after many years of asymptomatic bone loss. Because of the long
preclinical period, there is ample opportunity for intervention early in the course of
disease [17].
Our research has shown that if patients with prior wrist fractures could be
targeted with an intervention, then it is possible to reduce the number of
subsequent hip fractures and increase survival in postmenopausal white women.
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